Anxiolytic effects of lamotrigine and JZP-4 in the elevated plus maze and in the four plate conflict test

European Journal of Pharmacology

Volumn 602, Issue 2-3, 2009, Pages 316-320

  Foreman, Mark M ^a   Hanania, Taleen ^b   Eller, Mark ^a  

^a JAZZ PHARMACEUTICALS   (United States)

^b PSYCHOGENICS INC   (United States)

Author keywords

Anxiety disorders; Elevated plus maze; Four plate test; JZP 4; Lamotrigine

Indexed keywords

3 (2,3,5 TRICHLOROPHENYL)PYRAZINE 2,6 DIAMINE; ALPRAZOLAM; DIAZEPAM; JZP 4; LAMOTRIGINE; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONFLICT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; MALE; MAZE LEARNING; MICE; PUNISHMENT; PYRAZINES; TRIAZINES;

EID: 58149159545     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.11.013     Document Type: Article

References (24)

1. Anderson G.D. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 43 Suppl 3 (2002) 53-59
2. Aron C., Simon P., Larousse C., and Boissier J.R. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 10 (1971) 459-469
3. Bavdekar S.B., Muranjan M.N., Gogtay N.J., Kantharia V., and Kshirsagar N.A. Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment. Ann. Pharmacotherapy 38 (2004) 1648-1650
4. Berlin H.A. Antiepileptic drugs for the treatment of post-traumatic stress disorder. Current Psychiatry Rep. 9 (2007) 291-300
5. Bourin M., Hascoet M., Mansouri B., Colombel M.C., and Bradwejn J. Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J. Psychiatry Neuroscience 17 (1992) 72-77
6. Bowden C.L. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 19 (1998) 194-199
7. de-Paris F., Busnello J.V., Vianna M.R., Salgueiro J.B., Quevedo J., Izquierdo I., and Kapczinski F. The anticonvulsant compound gabapentin possesses anxiolytic but not amnesic effects in rats. Behav. Pharmacol. 11 (2000) 169-173
8. Ettinger A.B., and Argoff C.E. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 4 (2007) 75-83
9. Goldsmith D.R., Wagstaff A.J., Ibbotson T., and Perry C.M. Lamotrigine: a review of its use in bipolar disorder. Drugs 63 (2003) 2029-2050
10. Gower A.J., Falter U., and Lamberty Y. Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat. Eur. J. Pharmacol. 481 (2003) 67-74
11. Hascoet M., Bourin M., Colombel M.C., Ficco A.J., and Baker G.B. Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol. Biochem. Behav. 65 (2000) 339-344
12. Ketter T.A., Wang P.W., Chandler R.A., Alacon A.M., Becker O.V., Nowakowska C., O'Keeffe C.M., and Schumacher M.R. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J. Clin. Psychiatry 66 (2005) 642-645
13. Lauria-Horner B.A., and Pohl R.B. Pregabalin: a new anxiolytic. Expert Opin. Investig. Drugs 12 (2003) 663-672
14. Leach M.J., Randall A.D., Stefani A., and Hainsworth A.H. Lamotrigine: mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepleptic Drugs. Fifth Edition (2002), Lippincott, Williams and Wilkins, Philadelphia 363-369
15. Linden A.M., Greene S.J., Bergon M., and Scheopp D.D. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 29 (2004) 502-513
16. Maggs J.L., Naisbitt D.J., Tettey J.N., Pirmohaned M., and Park B.K. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem. Res. Toxicol. 13 (2000) 1075-1081
17. Mirza N.R., Bright J.L., Stanhope K.L., Wyatt A., and Harrington N.R. Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?. Psychopharmacology 180 (2005) 159-168
18. Mula M., Pini S., and Cassano G.B. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J. Clin. Psychopharmacol. 27 (2007) 263-272
19. Pellow S., and File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24 (1986) 525-529
20. Ring R.H., Malberg J.E., Potestio L., Ping J., Biokess S., Luo B., Schechter L.E., Rizzo S., Rahman Z., and Rosenzweig-Lipson S. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 185 (2006) 218-225
21. Schwartz T.L., and Nihalani N. Tiagabine in anxiety disorders. Expert Opin. Pharmacother. 7 (2006) 1977-1987
22. Soderpalm B., Lundin B., and Hjorth S. Sustained 5-hydroxytryptamine release-inhibitory and anxiolytic-like action of the partial 5-HT1A receptor agonist, buspirone, after prolonged chronic administration. Eur. J. Pharmacol. 239 (1993) 69-73
23. Weisler R.H., Cutler A.J., Ballenger J.C., Post R.M., and Ketter T.A. The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. CNS Spectrum 11 (2006) 788-799
24. Zangrossi Jr. H., Leite J.R., and Graeff F.G. Anxiolytic effect of carbamazepine in the elevated plus-maze: possible role of adenosine. Psychopharmacology 106 (1992) 85-89